Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 26 Show results per page	View Search Criteria \| Help With Results


1.		Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Natural history/Epidemiology				Completed				18 to 65				Pharmaceutical / Industry				0903X-100847 NCT00161668

Last Modified: 12/29/2008 First Published: 8/24/2004


2.		Phase II/III Randomized Study of Gemtuzumab Ozogamicin in Older Patients With Previously Untreated Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				61 and over				Other				EORTC-06031 NCT00091234

Last Modified: 11/20/2008 First Published: 11/1/2002


3.		Phase III Randomized Study of Daunorubicin and Cytarabine With or Without Gemtuzumab Ozogamicin Followed By Autologous Hematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia (Autologous Transplantation Arm II Closed to Accrual as of 10/4/2007)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 to 60				NCI				ECOG-1900 E1900, NCT00049517

Last Modified: 8/16/2007 First Published: 11/24/2002


4.		Phase III Randomized Study of Standard Induction Chemotherapy With or Without Gemtuzumab Ozogamicin in Elderly Patients With Previously Untreated Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				61 to 75				Other				EORTC-06012 AML-17, NCT00052299, GIMEMA-AML-17

Last Modified: 5/28/2007 First Published: 7/15/2005


5.		Phase III Randomized Study of Induction Therapy Comprising Cytarabine in Combination With Two Different Doses of Daunorubicin Followed By Cytarabine Alone With or Without Post-Induction Therapy Comprising Gemtuzumab Ozogamicin in Older Patients With Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts (RAEB), or RAEB in Transformation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				61 and over				Other				SAKK-AML-43 EU-20514, HOVON-AML-43, NCT00121303


6.		Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				21 and under				NCI, Other				AMLO2 NCT00136084


7.		Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				55 to 75				Other				ID01-010 NCT00038831


8.		A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				KAN-979-02 NCT00233909

Last Modified: 8/17/2007 First Published: 2/1/1998


9.		Phase II Study of CMA-676 in Patients with Acute Myeloid Leukemia in First Relapse

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				W-AR-0903B1-201-US UCCRC-8600, NCI-V97-1355, NCT00003131

Last Modified: 8/17/2007 First Published: 4/1/1999


10.		Phase II Study of CMA-676 in Elderly Patients with Acute Myeloid Leukemia in First Relapse

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				60 and over				Pharmaceutical / Industry				W-AR-0903B1-203-US NCI-V98-1497, NCT00003673

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute